

# CUMULATIVE INDEX 2001

## Volume 19

---

January	SYSTEMIC DERMATOLOGIC THERAPY, pages 1-218
April	DERMOSCOPY AND NEW IMAGING TECHNIQUES, pages 221-396
July	FUNDAMENTALS OF COSMETIC SURGERY, pages 401-577
October	MEDICAL DERMATOLOGY, pages 583-797

---

Note: Page numbers of article titles are in **boldface** type.

- Abacavir, for HIV infections, 26-27, 761-762  
 ABCD rule of dermoscopy, indications for, 344  
 ABX-IL-8, for psoriasis, 652  
 Achyal, in soft-tissue augmentation, 501  
 Acitretin, for cutaneous T-cell lymphoma, 740-741  
     for psoriasis, 164-165  
 Acne, chemical peels and, 434  
     hormonal therapy for, 173-175  
     isotretinoin for, 163-164  
 Acneiform eruptions, dapsone for, 82  
 Acquired melanocytic nevi. See *Benign melanocytic nevi*.  
 Actinic keratoses, chemical peels for, 419-421  
 Actinic prurigo, thalidomide for, 94-95  
 Actinic reticuloid, azathioprine for, 109  
 Acyclovir, for herpes simplex virus infections, 23-24  
     for varicella-zoster virus infections, 24-25  
 Adatosil-5000, in soft-tissue augmentation, 502-503  
 Adefovir, for chronic viral hepatitis, 30  
     for HIV infections, 28, 769  
 Adrenal suppression, for hirsutism, 175  
 Agranulocytosis, dapsone and, 83-84  
 AIDS, and telogen effluvium, 714  
     Kaposi's sarcoma with, interferons for, 141-142  
 Alefacept, for psoriasis, 654-655  
 Alexandrite laser therapy, for leg veins, 472  
 Allergic dermatitis, erbium:YAG laser resurfacing and, 462  
     tumor necrosis factor- $\alpha$  in, 620  
 AlloDerm, in soft-tissue augmentation, 503  
     indications for, 558  
 Alopecia, androgenetic, hair follicle miniaturization in, 720  
     hormonal therapy for, 176-177  
     cyclophosphamide and, 116  
     cyclosporine for, 125  
     tacrolimus for, 130  
 Alopecia areata, anagen arrest in, 716  
     hair follicle miniaturization in, 720-721  
 Amelanotic melanoma, diagnostic clues in, 565  
 Amenorrhea, glucocorticosteroids and, 73  
 Amitriptyline, dermatologic uses of, 181-182  
 Amprenavir, for HIV infections, 28, 767  
 Anagen arrest. See *Hair disorders*.  
 Anagen phase, of hair growth, 711-712  
 ANCA tests, of cutaneous vasculitis, 612  
 Androgen receptor blockade, for acne, 174  
     for hirsutism, 176  
 Androgen receptors, dermatologic uses of, 170  
 Androgenetic alopecia, hair follicle miniaturization in, 720  
     hormonal therapy for, 176-177  
 Androgens, circulating, dermatologic uses of, 170  
 Anesthesia, in erbium:YAG laser resurfacing, 459  
     surgical tips for, 575, 775-777  
     systemic, for mastocytosis, 690  
 Anesthetic effects, of antimalarial agents, 150  
 Anti CD-80, for psoriasis, 653-654  
 Anti CD11a Hu1124, for psoriasis, 653  
 Antibiotics, 1-21  
     cephalosporins, 1-5  
         adverse effects of, 4-5  
         antimicrobial activity of, 1  
         dermatologic uses of, 3  
         drug interactions with, 4  
         pharmacokinetics of, 3  
     clindamycin, 15  
         adverse effects of, 15  
         dermatologic uses of, 15  
         dosage of, 15  
         drug interactions with, 15  
         pharmacokinetics of, 15  
     fluoroquinolones, 9-10  
         adverse effects of, 10  
         antimicrobial activity of, 9  
         dermatologic uses of, 10  
         dosage of, 10  
         drug interactions with, 10  
         pharmacokinetics of, 9-10  
      $\beta$ -lactam, 5-7  
         adverse effects of, 6  
         antimicrobial activity of, 6  
         carbapenems, 6-7  
             adverse effects of, 7  
             antimicrobial activity of, 7  
             dermatologic uses of, 7  
             dosage of, 7  
             drug interactions with, 7  
             pharmacokinetics of, 7  
         dermatologic uses of, 6  
         dosage of, 6

Antibiotics (*Continued*)

- drug interactions with, 6
- pharmacokinetics of, 6
- macrolides, 8-9
  - adverse effects of, 9
  - antimicrobial activity of, 8
  - dermatologic uses of, 9
  - dosage of, 9
  - drug interactions with, 9
  - pharmacokinetics of, 8-9
- monobactams, 7-8
  - adverse effects of, 8
  - dermatologic uses of, 8
  - dosage of, 8
- prophylactic, in erbium:YAG laser resurfacing, 459
- rifamycins, 10, 12-13
  - adverse effects of, 12
  - antimicrobial activity of, 10
  - dermatologic uses of, 12
  - dosage of, 12-13
  - drug interactions with, 12
  - pharmacokinetics of, 12
- streptogramins, 15-16
  - adverse effects of, 16
  - antimicrobial activity of, 15-16
  - dermatologic uses of, 16
  - dosage of, 16
  - drug interactions with, 16
  - pharmacokinetics of, 16
- tetracyclines, 13-14
  - adverse effects of, 13-14
  - dermatologic uses of, 13
  - drug interactions with, 13
  - pharmacokinetics of, 13
- trimethoprim-sulfamethoxazole, 14-15
  - adverse effects of, 14-15
  - antimicrobial activity of, 14
  - dermatologic uses of, 14
  - dosage of, 15
  - drug interactions with, 14
  - pharmacokinetics of, 14
- Anti-cytokines, for toxic epidermal necrolysis, 706-707
- Antidepressants. *See* *Psychiatric agents*.
- Antifungal agents, 35-52
  - cost of, 46
  - fluconazole, 42-44
    - adverse effects of, 43
    - dermatologic uses of, 42-43
    - drug interactions with, 43
    - pharmacology of, 42
    - therapeutic and monitoring guidelines for, 43-44
  - griseofulvin, 35-37
    - adverse effects of, 36-37
    - dermatologic uses of, 36
    - drug interactions with, 37
    - pharmacology of, 35-36
    - therapeutic and monitoring guidelines for, 37
  - itraconazole, 39-42
    - adverse effects of, 41
    - dermatologic uses of, 40-41
    - drug interactions with, 41
    - pharmacology of, 39-40
    - therapeutic and monitoring guidelines for, 41-42
  - ketoconazole, 38-39
    - adverse effects of, 38-39
    - dermatologic uses of, 38
    - drug interactions with, 39
    - pharmacology of, 38
    - therapeutic and monitoring guidelines for, 39
  - terbinafine, 44-46
    - adverse effects of, 45
    - dermatologic uses of, 44-45
    - drug interactions with, 45-46
    - pharmacology of, 44
    - therapeutic and monitoring guidelines for, 46
- Antigen-presenting cells, in psoriasis, 650
- Antihistamines, 53-62
  - cetirizine, 58-59
    - adverse effects of, 58-59
    - dermatologic uses of, 58
    - drug interactions with, 58-59
    - pharmacology of, 58
  - chlorpheniramine, 57
    - dermatologic uses of, 57
    - pharmacology of, 57
  - cycloheptadine, 57-58
    - adverse effects of, 57-58
    - dermatologic uses of, 57
    - drug interactions with, 57-58
    - pharmacology of, 57
  - doxepin, 60
    - adverse effects of, 60
    - dermatologic uses of, 60, 181
    - drug interactions with, 60
    - pharmacology of, 60
  - fexofenadine, 59
    - adverse effects of, 59
    - dermatologic uses of, 59
    - drug interactions with, 59
    - pharmacology of, 59
  - historical aspects of, 53-54
  - hydroxyzine, 55, 57
    - adverse effects of, 57
    - dermatologic uses of, 57
    - drug interactions with, 57
    - pharmacology of, 55, 57
    - involvement of, in skin diseases, 54-55
  - ketotifen, 59-60
    - adverse effects of, 60
    - dermatologic uses of, 60
    - drug interactions with, 60
    - pharmacology of, 59-60
  - loratadine, 58
    - adverse effects of, 58
    - dermatologic uses of, 58
    - drug interactions with, 58
    - pharmacology of, 58
    - mechanism of action of, 54
- Antihyperlipidemic effects, of antimalarial agents, 151
- Anti-interleukin-8, for psoriasis, 652
- Antimalarial agents, 147-160
  - adverse effects of, 154-157
    - central nervous system, 155
    - cutaneous and pigmentary, 155
    - generalized and gastrointestinal, 154
    - hematologic, 155-156
    - musculoskeletal and myopathy, 154-155
    - ophthalmologic, 156-157
  - clinical studies of, 152-154
    - for cutaneous lupus erythematosus, 152
    - for pediatric dermatoses, 154
    - for polymorphous light eruption and solar urticaria, 153
    - for porphyria cutanea tarda, 152-153
    - for psoriasis, 153-154
    - for sarcoidosis, 153
    - for Sjögren's syndrome, 153
    - in pregnancy, 154
  - dosage of, 148
  - historical aspects of, 147

- mechanism of action of, 149-152  
 anesthetic effects, 150  
 antihyperlipidemic effects, 151  
 antioxidant effects, 150  
 antiplatelet effects, 151  
 combination therapy, 151-152  
 direct effects on cellular DNA, 150  
 hypoglycemic effects, 151  
 immunologic effects at cellular level, 149-150  
 smoking and, 152  
 synergy, 151  
 pharmacokinetics of, 147-148
- Antimetabolites. *See Cytotoxic agents.*
- Antioxidant effects, of antimalarial agents, 150
- Antiphospholipid antibody syndromes, leg ulcers in, 668-670
- Antiplatelet effects, of antimalarial agents, 151
- Antiviral agents, 23-33  
 for chronic viral hepatitis, 28-30  
   adefovir, 30  
   famciclovir, 30  
   interferons, 29  
   interferons and ribavirin, 29-30  
   lamivudine, 30  
 for cytomegalovirus, 30-31  
   cidofovir, 31  
   foscarnet, 31  
   ganciclovir, 30-31  
 for herpes simplex and varicella-zoster viruses, 23-26  
   acyclovir, 23-25  
   famciclovir, 25-26  
   foscarnet, 26  
   valacyclovir, 25  
 for HIV infections, 26-28, 757-772  
   investigational, 769  
   nucleoside reverse transcriptase inhibitors, 27-28, 762-764  
   nucleoside reverse transcriptase inhibitors, 26-27, 758-762, 769  
   nucleotide reverse transcriptase inhibitors, 28, 769  
   postexposure prophylactic, 768-769  
   protease inhibitors, 28, 764-767, 769  
   toxicities of, 767-768
- Aphthous stomatitis, thalidomide for, 90
- Aplastic anemia, antimalarial agents and, 155-156
- Apligraf, indications for, 559-560
- Apoptosis, ultraviolet-induced, tumor necrosis factor- $\alpha$  with, 619
- Argininosuccinic aciduria, and hair shaft defects, 721
- Artecoll, in soft-tissue augmentation, 503-504
- Arteplast, in soft-tissue augmentation, 505
- Arterial embolism, leg ulcers in, 663-664
- Arterial thrombosis, leg ulcers in, 663-664
- Arteriosclerosis obliterans, leg ulcers in, 662-663
- Arthritis, psoriatic, etanercept for, 622  
 rheumatoid. *See Rheumatoid arthritis.*
- Atherosclerosis, glucocorticosteroids and, 72
- Atopic dermatitis, azathioprine for, 108-109  
 tacrolimus for, 129-130
- Atopy, and drug reactions, 704
- Atrophie blanche, leg ulcers in, 666-667
- Atypical nevi, dermoscopy of, 275-277, 280  
 versus early melanoma. *See Melanoma.*
- Autoimmune blistering diseases, treatment of, 637-648  
 bullous pemphigoid, 637-639  
   cyclosporine in, 125  
   dapson in, 81-82  
   epidermolysis bullosa acquisita, 641-642  
   linear IgA bullous dermatosis, 642-643  
   mucous membrane pemphigoid, 639-641  
   mycophenolate mofetil in, 106  
   pemphigus, 643-645
- Autologen, in soft-tissue augmentation, 502
- Azathioprine. *See Cytotoxic agents.*
- Azithromycin. *See Antibiotics, macrolides.*
- Aztreonam. *See Antibiotics, monobactams.*
- Bacterial infections, erbium:YAG laser resurfacing and, 462-463
- Baker's phenol, in chemical peels, complications of, 429-430, 433
- Basal cell carcinoma, dispersed pattern, diagnostic clues in, 565  
 interferons for, 142  
 pigmented, clinical features of, 333
- Behçet's disease, cyclosporine for, 124  
 interferons for, 143  
 tacrolimus for, 130-131  
 thalidomide for, 91-92
- Benign lesions, versus cancerous lesions, diagnostic clues in, 564-565
- Benign melanocytic nevi, clinical features of, 332  
 dermoscopy of, 269-284  
   acquired lesions, 272-283  
     atypical nevi, 275-277, 280  
     blue nevi, 282  
     common melanocytic nevi, 272-275  
     halo nevi, 282-283  
     Spitz nevi, 280-282  
   congenital lesions, 270-272  
   versus malignant lesions, 269-270
- Bexarotene, for cutaneous T-cell lymphoma, 166, 741
- Biaxin. *See Antibiotics, macrolides.*
- Biobrane, indications for, 557
- Biocell Ultravital, in soft-tissue augmentation, 505
- Biochemotherapy, for melanoma, 729
- Bioengineered skin, for leg ulcers, 676
- Biologic response modifiers, for melanoma, 729
- Bioplastique, in soft-tissue augmentation, 505
- Biopsies, of sentinel lymph nodes, in melanoma, 728  
 of skin, in mastocytosis, 687  
 in pemphigus, 643-644  
 surgical tips for, 565, 568, 784
- Bis-POC, for HIV infections, 769
- Bjornstad's syndrome, and hair shaft defects, 721
- Bladder cancer, cyclophosphamide and, 116
- Bleach-Eze, in chemical peels, of darker skin types, 438
- Blepharoplasty. *See Brow lift and blepharoplasty.*
- Blistering diseases, autoimmune. *See Autoimmune blistering diseases.*
- Blue nevi, clinical features of, 332  
 dermoscopy of, 282
- Blue toe syndrome, leg ulcers in, 663
- Blue-white veil, in dermoscopy, of melanoma, 300-301  
 of pigmented lesions, 222  
   histopathologic correlates of, 263
- BMS-232632, for HIV infections, 769
- Body dysmorphic disorder, selective serotonin reuptake inhibitors for, 185
- Bone marrow lesions, in mastocytosis, 686
- Bone scans, of mastocytosis, 688
- Borders, in dermoscopy, of pigmented lesions, 255
- Botox, for aging neck, 395  
 in brow lift and blepharoplasty, 531  
 in soft-tissue augmentation, 500
- Bovine collagen products, in soft-tissue augmentation, 504
- Branched streaks, in dermoscopy, of pigmented lesions, 249-250

- Breslow thickness, in melanoma, 727, 728
- Brow lift and blepharoplasty, 531-533  
and orbital hemorrhage, 533  
bicoronal lift, 531-532  
Botox in, 531  
endoscopic, 532  
midbrow lift, 532  
preoperative evaluation for, 532-533  
pretrichial lift, 532  
temporal lift, 532  
transblepharoplasty lift, 532  
transconjunctival lower lid blepharoplasty, 533
- Buccal fat pad, fat grafting in, 525-526, 528, 530
- Buerger's disease, leg ulcers in, 663
- Bullous diseases. *See Autoimmune blistering diseases.*
- Cadaveric allografts, indications for, 558
- Calciphylaxis, leg ulcers in, 667-668
- Cancerous lesions, versus benign lesions, diagnostic clues in, 564-565
- Candida* infections, fluconazole for, 43
- Carbapenems. *See Antibiotics.*
- Carbon dioxide, in chemical peels, 414
- Carbon dioxide laser resurfacing, 443-451, 453-454  
advantages of, 443  
indications for, 443  
physics of, 443-444  
technique for, 445, 447-448, 450
- Cardiac arrhythmias, chemical peels and, 435
- Cardiac conduction abnormalities, tricyclic antidepressants and, 183
- Cardiovascular effects, of glucocorticosteroids, 72
- Cataracts, glucocorticosteroids and, 70-71
- Central nervous system effects, of antimalarial agents, 155
- Central white patch, in dermoscopy, of pigmented lesions, histopathologic correlates of, 267
- Cephalosporins. *See Antibiotics.*
- Cetirizine. *See Antihistamines.*
- Cheekbone, fat grafting in, 528
- Chemical irritants, in sclerotherapy, 476
- Chemical peels, 405-411, 419-421  
application techniques in, 408-409  
Baker's phenol in, complications of, 429-430, 433  
choosing agent for, 407-408  
complications of, 410, 427-438  
acne, 434  
atrophy, 434-435  
cardiac arrhythmias, 435  
cold sensitivity or cold urticaria, 434  
errors inherent to procedure, 436  
exacerbation of concurrent disease, 435-436  
infections, 432-433  
laryngeal edema, 435  
milium, 433-434  
pigmentary changes, 406-407, 428-429  
poor physician/patient relationship, 434  
prolonged erythema or pruritus, 433  
scarring, 429-432  
textural changes, 433  
for aging neck, 390  
for scarring, 407  
herpes simplex virus infections and, 407  
in darker skin types, bleaching solution for, 438  
line of demarcation in, 406  
medium-depth, 413-425  
complications of, 422-424  
components of, 418  
indications for, 413  
postoperative care for, 422-424  
trichloroacetic acid in, 407-409, 413-424  
anatomic sequence in, 417-418  
application of, 416  
areas needing special attention in, 418  
CO<sub>2</sub> application before, 414  
complications of, 429  
glycolic acid application before, 414  
indications for, 418-420  
Jessner's solution application before, 414-424  
level of frosting in, 416-417  
postoperative care for, 418  
results of, 420-421  
skin preparation, 415  
pain relief in, 409  
patient selection for, 405-406  
postoperative care for, 409-410  
preoperative preparation for, 409
- Chemotherapy, and anagen arrest, 716  
for mastocytosis, 691  
for melanoma, 729  
thalidomide in, 628
- Chin, fat grafting in, 528
- Chloroquine. *See Antimalarial agents.*
- Chlorpheniramine. *See Antihistamines.*
- Cholesterol emboli syndrome, leg ulcers in, 663
- Chondritis, in wound repair, 795
- Cicatricial pemphigoid, cyclophosphamide for, 115
- Cidofovir, for cytomegalovirus infections, 31
- Cigarette smoking, and antimalarial therapy, 152
- Cilastatin. *See Antibiotics, carbapenems.*
- Ciprofloxacin. *See Antibiotics, fluoroquinolones.*
- Citalopram. *See Psychiatric agents, selective serotonin reuptake inhibitors.*
- Clarithromycin. *See Antibiotics, macrolides.*
- Clindamycin. *See Antibiotics.*
- Clomipramine, dermatologic uses of, 181-182
- Cold sensitivity, chemical peels and, 434
- Cold urticaria, chemical peels and, 434
- Collagen injections. *See Soft-tissue augmentation.*
- Comedo-like structures, in dermoscopy, of pigmented lesions, 252  
histopathologic correlates of, 265
- Common melanocytic nevi, dermoscopy of, 272-275
- Composite skin grafts, indications for, 559-560
- Compound nevi, in vivo confocal microscopy of, 373-374
- Compression therapy, after sclerotherapy, 479-480  
for leg ulcers, 675
- Condylomata acuminata, interferons for, 141
- Congenital melanocytic nevi, dermoscopy of, 270-272
- Connective tissue diseases, griseofulvin for, 36
- Contact dermatitis, erbium:YAG laser resurfacing and, 462  
in wound repair, 793  
tumor necrosis factor- $\alpha$  in, 620
- Contraceptives, oral, dermatologic uses of, 171
- Cool Touch-V laser therapy, for leg veins, 472
- Corneal deposition, of antimalarial agents, 156
- Cosmetic surgery, brow lift and blepharoplasty in. *See Brow lift and blepharoplasty.*  
carbon dioxide laser resurfacing in. *See Carbon dioxide laser resurfacing.*  
chemical peels in. *See Chemical peels.*  
dermabrasion in. *See Dermabrasion.*  
dermal grafting in. *See Dermal grafting.*  
erbium:YAG laser resurfacing in. *See Erbium:YAG laser resurfacing.*  
fat grafting in. *See Fat grafting.*

- for photoaging skin. See *Photoaging skin*.  
 laser therapy in. See *Laser therapy*.  
 liposuction in. See *Liposuction*.  
 sclerotherapy in. See *Sclerotherapy*.  
 soft-tissue augmentation in. See *Soft-tissue augmentation*.
- Crohn's disease, aphthae in, thalidomide for, 92  
 infliximab for, 625  
 tumor necrosis factor- $\alpha$  in, 620
- Cryofibrinogenemia, leg ulcers in, 669-670
- Cryoglobulinemia, leg ulcers in, 669-670
- CTLA4lg, for psoriasis, 655
- Cutaneous effects, of antimalarial agents, 155  
 of glucocorticosteroids, 74
- Cutaneous lupus erythematosus, antimalarial agents for, 152
- Cutaneous T-cell lymphoma, 737-748  
 future treatments for, 744  
 interferons for, 142, 737-740  
 with psoralen plus ultraviolet A therapy, 739-740  
 interleukins for, 742-744  
 retinoids for, 740-742  
 bexarotene, 166, 741  
 isotretinoin, etretinate, and acitretin, 740-741  
 topical, 741-742
- Cutaneous vasculitis, 603-615  
 classification of, 606, 609-610  
 diagnosis of, direct immunofluorescence in, 610-612  
 laboratory tests in, 612-613  
 etiology of, 603, 605  
 leg ulcers in, 664  
 pathogenesis of, 605-606  
 treatment of, 613-614
- Cyclophosphamide. See *Cytotoxic agents*.
- Cyclosporine, 119-129  
 adverse effects of, 126-128  
 cautions in, 129  
 dermatologic uses of, 122-126  
 alopecia, 125  
 Behçet's disease, 124  
 bullous dermatoses, 125  
 eczematous dermatoses, 124-125  
 epidermolysis bullosa acquisita, 641-642  
 lichen planus, 125  
 photodermatoses, 124  
 psoriasis, 123-124  
 pyoderma gangrenosum, 124  
 toxic epidermal necrolysis, 125-126  
 dosage of, 126  
 drug interactions with, 126  
 monitoring guidelines for, 128-129  
 pharmacology of, 119-120, 122
- Cymetra, in soft-tissue augmentation, 503
- Cyproheptadine. See *Antihistamines*.
- Cyproterone acetate, dermatologic uses of, 172-173
- Cytokines, for psoriasis, 651-652  
 in psoriasis, 650
- Cytomegalovirus infections, antiviral agents for. See *Antiviral agents*.
- Cytotoxic agents, 105-118  
 azathioprine, 108-110  
 adverse effects of, 110  
 dermatologic uses of, 108-109  
 bullous pemphigoid, 638  
 pemphigus, 644  
 dosage of, 109  
 drug interactions with, 109  
 monitoring guidelines for, 110
- cyclophosphamide, 114-116  
 adverse effects of, 116  
 dermatologic uses of, 114-115  
 mucous membrane pemphigoid, 640  
 pemphigus, 644, 645  
 dosage of, 115  
 drug interactions with, 116  
 monitoring guidelines for, 116
- methotrexate, 111-114  
 adverse effects of, 113-114  
 dermatologic uses of, 112-113  
 bullous pemphigoid, 638-639  
 rheumatoid arthritis, 625  
 dosage of, 113  
 drug interactions with, 113  
 monitoring guidelines for, 114
- mycophenolate mofetil, 105-108  
 adverse effects of, 107  
 dermatologic uses of, 106-107  
 bullous pemphigoid, 639  
 for pemphigus, 644  
 dosage of, 107  
 drug interactions with, 107  
 monitoring guidelines for, 108
- thioguanine, 110-111  
 adverse effects of, 111  
 dermatologic uses of, 110-111  
 dosage of, 111  
 drug interactions with, 111  
 monitoring guidelines for, 111
- Dacarbazine, for melanoma, 729
- Daclizumab, for psoriasis, 654
- Dapsone, 79-86  
 absorption and distribution of, 79-80  
 adverse effects of, 83-84  
 dermatologic uses of, 81-83  
 linear IgA bullous dermatosis, 642-643  
 pemphigus, 644  
 drug interactions with, 84  
 historical aspects of, 79  
 mechanism of action of, 80-81  
 metabolism and excretion of, 80  
 monitoring guidelines for, 84-85  
 structure of, 79
- Darier's sign, in mastocytosis, 685
- Delavirdine, for HIV infections, 27-28, 763-764
- Delusions of parasitosis, pimozide for, 191
- Democlocycline. See *Antibiotics, tetracyclines*.
- Dendritic cell vaccines, for melanoma, 732
- Denileukin diftitox, for cutaneous T-cell lymphoma, 732-744
- Depression, isotretinoin and, 164
- Dermabrasion, 439-442  
 complications of, 441-442  
 consultation for, 440  
 indications for, 439  
 instrumentation for, 440  
 patient selection for, 439  
 sedation for, 440  
 technique for, 440-441
- Dermal grafting, 509-522  
 complications of, 519  
 ideal substance for, 509  
 patient selection for, 510  
 rationale for, 509-510  
 results of, 519  
 technique for, 510-511, 513, 518  
 pull-through, 518-519
- Dermal nevi, clinical features of, 332

- Dermalive, in soft-tissue augmentation, 505  
 Dermalogen, in soft-tissue augmentation, 503  
 Dermatitis, azathioprine for, 108-109  
   erbium:YAG laser resurfacing and, 462  
   in wound repair, 793  
   tacrolimus for, 129-130  
   tumor necrosis factor- $\alpha$  in, 620  
 Dermatitis herpetiformis, dapsone for, 81-82  
 Dermatomyositis, methotrexate for, 112  
 Dermatophyte onychomycosis, itraconazole for, 40  
 Dermatoses, in children, antimalarial agents for, 154  
 Dermoscopy, digital. See *Digital dermoscopy*.  
   in risk stratification, for melanoma, 327-328  
   of benign melanocytic nevi. See *Benign melanocytic nevi*.  
   of early melanoma, 320-325  
   of lentigo maligna. See *Lentigo maligna*.  
   of lichenoid keratoses, 351, 353-355  
   of melanoma. See *Melanoma*.  
   of pigmented lesions. See *Pigmented lesions*.  
   of seborrheic keratoses, 347-348  
   of solar lentigines, 348-351  
 Desipramine, dermatologic uses of, 182  
 Detergent agents, in sclerotherapy, 476  
 Diabetic neuropathy, gabapentin for, 190  
 Didanosine, for HIV infections, 26-27, 761  
 Digit surgery, tips for. See *Surgical tips*.  
 Digital dermoscopy, 359-367  
   advantages of, 361  
   ease of transmission in, 362  
   feature extraction in, 363-364  
   historical aspects of, 360-361  
   image acquisition in, 359  
   image analysis in, 362-363  
   image archiving in, 361-362  
   image classification in, 364-365  
   indications for, 360  
   segmentation in, 363  
   software development in, 365  
   versus photographs, 361  
 Diode laser therapy, for leg veins, 472  
 Dirithromycin. See *Antibiotics, macrolides*.  
 Discoid lupus erythematosus, and hair follicle destruction, 718  
   thalidomide for, 93-94  
 Disodium cromoglycate, for mastocytosis, 690  
 Disorders of cornification, retinoids for, 165  
 Dots and globules, in dermoscopy, of melanoma, 301-303  
   of pigmented lesions, 240  
   histopathologic correlates of, 261  
 Doxepin. See *Antihistamines*.  
 Doxycycline. See *Antibiotics, tetracyclines*.  
 Dressings, tips for. See *Surgical tips*.  
 Drug reactions, 697-709  
   acute generalized exanthematic pustulosis, 698-700  
   atopy and, 704  
   drug metabolism and, 703-704  
   erythema multiforme, 700-703  
   hypersensitivity syndrome, 707  
   immune mechanisms in, 702-703  
   oral ulcers, 697-698  
   prognosis for, 704-705  
   Stevens-Johnson syndrome, 700-703  
   Sweet's syndrome, 698  
   toxic epidermal necrolysis, 700-703  
   treatment of, 704-707  
     anti-cytokines in, 706-707  
     steroids and immunosuppressants in, 706  
     symptomatic, 705  
     systemic drugs in, 707  
     withdrawal of drug in, 704  
   viral infections in, 702  
 Dynabac. See *Antibiotics, macrolides*.  
 Dyschromias, pigmentary, chemical peels for, 420-421  
 Dysplastic nevi, in vivo confocal microscopy of, 374  
   versus early melanoma. See *Melanoma*.  
 Ectropion, chemical peels and, 430  
   prevention of, tips for, 576-577  
 Eczematous dermatoses, cyclosporine for, 124-125  
 Edema, laryngeal, chemical peels and, 435  
 Efavirenz, for HIV infections, 27-28, 764  
 Ehrlichiosis, treatment of, 752-753  
 ELAMAX, in pain relief, after chemical peels, 409  
 Electrocardiographic changes, pimozide and, 192  
 E-mail, and telemedicine, 382  
 EMLA, in pain relief, after chemical peels, 409  
 Endocrinopathies, and telogen effluvium, 713  
 Endoplast-50, in soft-tissue augmentation, 505  
 Enoxacin. See *Antibiotics, fluoroquinolones*.  
 Epidermal grafts, indications for, 555-557  
 Epidermolysis bullosa acquisita, treatment of, 641-642  
 Epiluminescence microscopy. See *Dermoscopy*.  
 Epstein-Barr virus, chemical peels and, 433  
 Erbium:YAG laser resurfacing, 453-466  
   anesthesia in, 459  
   complications of, 461-463  
   contraindications to, 461  
   for aging neck, 390-391  
   indications for, 457-458  
   laser-tissue interaction in, 454-456  
   patient selection for, 456  
   physics of, 444, 454  
   postoperative care for, 460-461  
   preoperative preparation for, 458-459  
   technique for, 459-460  
 Erythema, chemical peels and, 431, 433  
   erbium:YAG laser resurfacing and, 461  
   in dermoscopy, of pigmented lesions, 222  
   toxin-mediated, 751  
 Erythema elevatum diutinum, diagnosis of, 609  
 Erythema multiforme, drug-induced, 700-703  
   thalidomide for, 96  
 Erythema nodosum leprosum, thalidomide for, 89-90  
 Erythromycin. See *Antibiotics, macrolides*.  
 Etanercept, for psoriasis, 652  
   to modulate tumor necrosis factor- $\alpha$ . See *Tumor necrosis factor- $\alpha$* .  
 Etretnate, for cutaneous T-cell lymphoma, 740-741  
   for psoriasis, 164-165  
 Exanthematous disease, in neonates, 752  
 Excoriations, psychogenic, selective serotonin reuptake inhibitors for, 185  
 Exophytic papillary structures, in dermoscopy, of pigmented lesions, histopathologic correlates of, 265-266  
 Extracorporeal photopheresis, for epidermolysis bullosa acquisita, 642  
 Eyelids, chemical peels of, 418  
   fat grafting in, 528  
 E-Z-Derm, indications for, 557  
 Facial flaps, for skin cancer, 199-212  
   anatomy in, 201  
   classification of, 202



- options in, 199-200
- patient expectations in, 207
- patient selection for, 200
- techniques for, 200-207
- Famciclovir, for chronic viral hepatitis, 30
- for herpes simplex virus infections, 25-26
- Fascian, in soft-tissue augmentation, 503
- Fat, in soft-tissue augmentation. *See Soft-tissue augmentation.*
- Fat atrophy, subcutaneous, glucocorticosteroids and, 74
- Fat grafting, 523-530
  - complications of, 526-527
  - donor sites for, 524-525
  - in buccal fat pad, 525-526, 528, 530
  - in cheekbone, 528
  - in chin, 528
  - in dorsal aspect of hand, 526
  - in eyelids, 528
  - in lips, 526, 530
  - in nasolabial fold, 530
  - indications for, 523
  - informed consent for, 523-524
  - recipient site in, 525
  - results of, 525-527
  - tumescent solution for, 525
- Fexofenadine. *See Antihistamines.*
- Fibroquel, in soft-tissue augmentation, 505
- Finasteride, dermatologic uses of, 173
- Fissures, in dermoscopy, of pigmented lesions, 252
- Fitzpatrick classification, of skin types, 402
- FK506. *See Tacrolimus.*
- Flashlamp-pumped pulsed dye laser therapy, for
  - erythema, after chemical peels, 431-432
- Fluconazole. *See Antifungal agents.*
- Fluoroquinolones. *See Antibiotics.*
- Fluoxetine. *See Psychiatric agents, selective serotonin reuptake inhibitors.*
- Flutamide, dermatologic uses of, 172
- Fluvoxamine. *See Psychiatric agents, selective serotonin reuptake inhibitors.*
- Follicular plugs, in dermoscopy, of pigmented lesions, 255
- Foscarnet, for cytomegalovirus infections, 31
- for herpes simplex virus infections, 26
- Fusion inhibitors, for HIV infections, 769
- Gabapentin. *See Psychiatric agents.*
- Ganciclovir, for cytomegalovirus infections, 30-31
- Ganglioside vaccines, for melanoma, 730
- Gastrointestinal effects, of antimalarial agents, 154
  - of cephalosporins, 4
  - of fluconazole, 43
  - of glucocorticosteroids, 73-74
  - of itraconazole, 41
  - of ketoconazole, 38
  - of  $\beta$ -lactam antibiotics, 6
  - of tetracyclines, 13-14
- Gastrointestinal features, of mastocytosis, 686
- Gene therapy, for melanoma, 732
- Glaucoma, glucocorticosteroids and, 71
- Globules, in dermoscopy. *See Dots and globules.*
- Glogau classification, of skin types, 402-403
- Glucocorticosteroids, 63-77
  - adverse effects of, 67-74
    - cardiovascular, 72
    - cutaneous, 74
    - gastrointestinal, 73-74
    - growth retardation, 70
    - hypothalamic-pituitary-adrenal axis suppression, 74
    - infectious, 72-73
    - metabolic, 71-72
    - myopathy, 70
    - nervous system, 71
    - obstetric and gynecologic, 73
    - ophthalmologic, 70-71
    - osteonecrosis, 69-70
    - osteoporosis, 67-69
  - dosage of, 66-67
    - alterations in, 67
  - drug interactions with, 67
  - effects of, on inflammatory cells, 65-66
  - hypothalamic-pituitary-adrenal axis and, 63-64
  - mechanism of action of, 65
  - pharmacology of, 64-65
- Glycolic acid, in chemical peels, 408, 414
- Gold therapy, for pemphigus, 644
- Graft-versus-host disease, and hair follicle destruction, 719-720
  - tacrolimus for, 131
  - thalidomide for, 92-93
- Granulation tissue, excessive, in wound repair, 793-794
- Granules, in dermoscopy, of pigmented lesions, 240
- Granulocyte macrophage-colony stimulating factor, for
  - leg ulcers, 676
  - for melanoma, 732
- Granulomatous vasculitis, diagnosis of, 610
- Griseofulvin. *See Antifungal agents.*
- Growth factors, in wound repair, 790
  - topical, for leg ulcers, 675-676
- Growth retardation, glucocorticosteroids and, 70
- Gynecologic effects, of glucocorticosteroids, 73
- H<sub>1</sub> antagonists, for mastocytosis, 690
- H<sub>2</sub> antagonists, for mastocytosis, 690
- Hair disorders, 711-726
  - anagen arrest, 715-718
    - alopecia areata and, 716
    - chemotherapy and, 716
    - inflammatory diseases and, 716
    - systemic lupus erythematosus and, 716
  - hair follicle destruction, 718-720
    - discoid lupus erythematosus and, 718
    - graft-versus-host disease and, 719-720
    - malignancies and, 719
    - mycosis fungoides and, 719
    - sarcoidosis and, 718
    - scleroderma and, 718
    - systemic lupus erythematosus and, 718
  - hair follicle miniaturization, 720-721
  - hair shaft defects, 721-722
  - hirsutism, 723-725
    - hypertrichosis, 722-723
  - telogen effluvium, 712-715
    - diagnosis of, 714-715
    - drug-induced, 713-714
    - endocrinopathies and, 713
    - HIV infections and, 714
    - postpartum, 713
    - versus normal growth, 711-712
- Hair follicle destruction. *See Hair disorders.*
- Hair follicle miniaturization, and hair loss, 720-721
- Hair shaft defects, and hair loss, 721-722
- Halo nevi, dermoscopy of, 282-283
- Hands, dorsal aspect of, fat grafting in, 526
- Heat-shock proteins, for melanoma, 731
- Help-G Versapulse laser therapy, for leg veins, 472

- Hemangiomas, infantile, interferons for, 142
- Hematologic effects, of antimalarial agents, 155-156  
of dapsone, 83-84
- Hematologic features, of mastocytosis, 686
- Hematologic studies, of mastocytosis, 689
- Hematomas, in wound repair, 791
- Hemoglobin, in dermoscopy, of pigmented lesions, 222  
histopathologic correlates of, 265
- Hemolysis, dapsone and, 83
- Hemophilia, increased bleeding in, antiretroviral therapy and, 768
- Hemorrhage, in wound repair, 791  
orbital, brow lift and blepharoplasty and, 533
- Hemostasis, surgical tips for, 573, 575
- Hepatic features, of mastocytosis, 686-687
- Hepatic steatosis, antiretroviral therapy and, 767-768
- Hepatic veno-occlusive disease, thioguanine and, 111
- Hepatitis, chronic viral, antiviral agents for. See *Antiviral agents*.
- Hepatotoxicity, of dapsone, 84  
of ketoconazole, 38-39
- Herpes simplex virus infections, activation of, by  
chemical peels, 432-433  
by erbium:YAG laser resurfacing, 462  
and chemical peels, 407  
antiviral agents for. See *Antiviral agents*.  
prevention of, in erbium:YAG laser resurfacing, 458-459
- Herpes zoster virus infections, amitriptyline for, 182
- Hirsutism, hormonal therapy for, 175-176  
mechanisms of, 723-725
- Histiocytosis X, thalidomide for, 95-96
- HIV infections, and aphthous ulceration, thalidomide for, 90-91  
and drug reactions, 702  
and hair shaft defects, 721-722  
and telogen effluvium, 714  
antiviral agents for. See *Antiviral agents*.  
thalidomide for, 627
- Hormonal therapy, 169-178  
cyproterone acetate, 172-173  
dermatologic uses of, 173-177  
acne, 173-175  
androgenetic alopecia, 176-177  
hirsutism, 175-176  
finasteride, 173  
flutamide, 172  
oral contraceptives, 171  
pretreatment evaluation for, 173  
rationale for, 169-171  
androgen receptors, 170  
circulating androgens, 170  
5 $\alpha$ -reductase, 170-171  
spironolactone, 172
- Human placental collagen, in soft-tissue augmentation, 504
- Hyaluronic acid products, in soft-tissue augmentation, 500-502
- Hydroxychloroquine. See *Antimalarial agents*.
- Hydroxyurea, for HIV infections, 769
- Hydroxyzine. See *Antihistamines*.
- Hylaform Gel, in soft-tissue augmentation, 501
- Hylan gels, in soft-tissue augmentation, 501
- Hylan Rofilan Gel, in soft-tissue augmentation, 501
- Hyperglycemia, antiretroviral therapy and, 768  
glucocorticosteroids and, 71-72
- Hyperlipidemia, antiretroviral therapy and, 768  
glucocorticosteroids and, 72
- Hyperpigmentation, chemical peels and, 406-407, 410, 428-429  
dermabrasion and, 441-442  
erbium:YAG laser resurfacing and, 462
- Hyperpigmented junctional nevi, clinical features of, 333
- Hypersensitivity reactions, drugs in, 707  
to cephalosporins, 4  
to dapsone, 84  
to Zyderm/Zyplast, 497
- Hypertension, cyclosporine and, 127-128  
glucocorticosteroids and, 72
- Hypertonic saline, in sclerotherapy, 481
- Hypertrichosis, mechanisms of, 722-723
- Hypertrichosis lanuginosa, mechanisms of, 723
- Hypertriglyceridemia, bexarotene and, 741
- Hypocalcemia, glucocorticosteroids and, 72
- Hypocomplementemic urticarial vasculitis, cyclophosphamide for, 115
- Hypoglycemic effects, of antimalarial agents, 151
- Hypokalemic alkalosis, glucocorticosteroids and, 72
- Hypopigmentation, chemical peels and, 407, 428-429  
dermabrasion and, 441  
erbium:YAG laser resurfacing and, 462  
in dermoscopy, of pigmented lesions, histopathologic correlates of, 264
- Hypothalamic-pituitary-adrenal axis suppression, glucocorticosteroids and, 74
- Hypothyroidism, bexarotene and, 741
- IDEA-114, for psoriasis, 653-654
- Imipenem. See *Antibiotics, carbapenems*.
- Immune deviation, for psoriasis, 653
- Immunofluorescence studies, of cutaneous vasculitis, 610-612
- Immunoglobulin, intravenous, for mucous membrane pemphigoid, 641  
for toxic epidermal necrolysis, 706
- Immunosuppressants, for toxic epidermal necrolysis, 706
- Immunosuppression, ultraviolet-induced, tumor necrosis factor- $\alpha$  with, 619
- Immunotherapy, for melanoma, 729-732
- In vivo confocal microscopy, 369-377  
dynamic imaging in, 374-375  
of nonmelanoma skin cancer, 371, 373  
of normal skin, 371  
of pigmented skin lesions, 373-374  
of proliferative skin lesions, 371  
principles of, 369-371
- Indinavir, for HIV infections, 28, 766
- Infantile hemangiomas, interferons for, 142
- Infections, antibiotics for. See *Antibiotics*.  
chemical peels and, 410, 432-433  
dapsone for, 82-83  
erbium:YAG laser resurfacing and, 462-463  
glucocorticosteroids and, 72-73  
in wound repair, 791-792  
viral, and drug reactions, 702
- Infectious diseases, 749-756  
cutaneous *Vibrio* infections, 753-754  
human ehrlichiosis, 752-753  
necrotizing fasciitis, 752  
*Penicillium marneffei* infection, 753  
toxin-mediated streptococcal and staphylococcal disease, 749-752  
erythema, 751  
neonatal exanthematous disease, 752  
recalcitrant, erythematous, desquamating, 751  
renewed virulence of, 749-750



- streptococcal toxic shock syndrome, 750-751  
toxic shock syndrome, 750
- Inflammatory bowel disease, isotretinoin and, 164
- Inflammatory diseases, and anagen arrest, 716  
thalidomide for, 627
- Inflammatory response, tumor necrosis factor- $\alpha$  in, 620
- Infliximab, for psoriasis, 651-652  
to modulate tumor necrosis factor- $\alpha$ . See *Tumor necrosis factor- $\alpha$* .
- Ink spot lentigo, clinical features of, 333
- Integra, indications for, 558
- Integrase inhibitors, for HIV infections, 769
- Interferons, 139-146  
adverse effects of, 140-141  
dermatologic uses of, 141-143  
AIDS-associated Kaposi's sarcoma, 141-142  
basal cell and squamous cell carcinoma, 142  
Behçet's disease, 143  
chronic viral hepatitis, 29  
with ribavirin, 29-30  
condylomata acuminata, 141  
cutaneous T-cell lymphoma, 142, 737-740  
with psoralen plus ultraviolet A therapy, 739-740  
keloids, 143  
mastocytosis, 691  
melanoma, 141, 729  
skin cancer, with retinoids, 166  
vascular tumors, 142  
dosage of, 143-144  
mechanism of action of, 139  
nondermatologic uses of, 143  
pharmacokinetics of, 140
- Interleukins, for cutaneous T-cell lymphoma, 742-744  
for melanoma, 729
- Internet, and telemedicine, 380-381  
prehistory of, 381-382
- Irritant dermatitis, tumor necrosis factor- $\alpha$  in, 620
- Isolagen, in soft-tissue augmentation, 502
- Isotretinoin, for acne, 163-164  
for cutaneous T-cell lymphoma, 740-741
- Itraconazole. See *Antifungal agents*.
- Jessner's lymphocytic infiltration, of skin, thalidomide in, 96
- Jessner's solution, in chemical peels, 408, 414-424  
formula for, 416
- Junctional nevi, hyperpigmented, clinical features of, 333  
in vivo confocal microscopy of, 373-374
- Kaposi's sarcoma, interferons for, 141-142  
thalidomide for, 97
- Keloids, interferons for, 143
- Keratinocyte growth factor, for leg ulcers, 676
- Keratoses, lichenoid, dermoscopy of, 351, 353-355  
seborrhic, clinical features of, 333  
dermoscopy of, 347-348
- Ketoconazole. See *Antifungal agents*.
- Ketotifen. See *Antihistamines*.
- Kinky hair disease, and hair shaft defects, 721
- Koken Atelocollagen, in soft-tissue augmentation, 504
- KTP laser therapy, for leg veins, 472
- Lactation, glucocorticosteroids and, 73
- Lactic acidosis, antiretroviral therapy and, 767-768
- Lacunae, in dermoscopy, of pigmented lesions, 222  
histopathologic correlates of, 266-267
- Lamivudine, for chronic viral hepatitis, 30  
for HIV infections, 26-27, 759, 761, 762
- Langerhans' cell histiocytosis, thalidomide for, 95-96
- Laryngeal edema, chemical peels and, 435
- Laser resurfacing, carbon dioxide. See *Carbon dioxide laser resurfacing*.  
chemical peels with, 420  
erbium:YAG. See *Erbium:YAG laser resurfacing*.  
for aging neck, 390-391
- Laser therapy, for erythema, after chemical peels, 431-432  
for leg veins, 467-473  
clinical studies of, 471-472  
physics of, 467-473  
epidermal cooling, 469  
pulse duration, 468-469  
spot size, 469  
variable vessel depth, 470-471  
wavelength, 467-468  
in vivo confocal microscopy after, 375
- Leaf-like structures, in dermoscopy, of pigmented lesions, 255  
histopathologic correlates of, 267
- Leflunomide, for bullous pemphigoid, 639
- Leg ulcers, 659-678  
bioengineered skin for, 676  
compression therapy for, 675  
diagnosis of, imaging in, 660  
laboratory tests in, 660  
patient evaluation in, 659  
ulcer-specific examination in, 659-660  
wound cultures in, 660-661  
hypertensive ischemic, 667  
in antiphospholipid antibody syndromes, 668-670  
in arterial occlusion, 663-664  
in atrophie blanche, 666-667  
in calciphylaxis, 667-668  
in cryoglobulinemia and cryofibrinogenemia, 669-670  
in cutaneous vasculitis, 664  
in livedo reticularis and vasculitis, 664-666  
in pyoderma gangrenosum, 671-673  
in Raynaud's disease or phenomenon, 661-662  
in thromboangiitis obliterans, 663  
in venous stasis dermatitis, 670  
rate of healing in, 675  
tissue necrosis in, 674-675  
topical growth factors for, 675-676  
treatment algorithm for, 673  
venous, 670-671  
wound drainage in, 674
- Leg veins, laser therapy for. See *Laser therapy*.
- Lentigines, solar, dermoscopy of, 348-351
- Lentiginous epidermal hyperplasia, dermoscopy of, 349, 351
- Lentigo maligna, clinical course of, 308-309  
clinical features of, 308  
dermoscopy of, 307-318  
clinicopathologic correlates of, 311-312, 317  
diagnosis of, accuracy of, 309-311  
etiology of, 308  
incidence of, 307-308
- Leprosy, dapsone for, 82-83
- Levofloxacin. See *Antibiotics, fluoroquinolones*.
- Lichen planus, cyclosporine for, 125  
mycophenolate mofetil for, 107  
tacrolimus for, 131
- $\beta$ -Lactam antibiotics. See *Antibiotics*.

Lichen planus (*Continued*)

- thalidomide for, 97
- Lichenoid keratoses, dermoscopy of, 351, 353-355
- Linear IgA bullous dermatosis, treatment of, 642-643
- Lipodystrophy, antiretroviral therapy and, 768
- Liposculpture, for aging neck, 392, 395
- Liposuction, 483-489
  - complications of, 487
  - patient selection for, 483
  - postoperative care for, 487
  - preoperative preparation for, 485
  - results of, 487
  - technique for, 485-487
- Lips, enhancement of, Zyderm/Zyplast in, 496-497
  - fat grafting in, 526, 530
- Livedo reticularis, leg ulcers in, 664-666
- Livedo vasculitis, leg ulcers in, 664-666
- Lomefloxacin. *See Antibiotics, fluoroquinolones.*
- Lopinavir, for HIV infections, 767
- Loratadine. *See Antihistamines.*
- Lotus Notes, and telemedicine, 382-383
- Lymph nodes, involvement of, by mastocytosis, 686
- Lymphocytic cutaneous vasculitis, diagnosis of, 606, 609
  - treatment of, 613
- Lymphoma, cutaneous T-cell. *See Cutaneous T-cell lymphoma.*
- Lymphomatoid papulosis, methotrexate for, 112-113

Macrolides. *See Antibiotics.*

## Magnetic resonance imaging, of mastocytosis, 688

## Malignancies, and hair follicle destruction, 719

## Maprotiline, dermatologic uses of, 182

## Martorell's ulcer, diagnosis of, 667

## Mastocytosis, 679-696

- bone marrow lesions in, 686
- cutaneous lesions in, 684-685
- diagnosis of, hematologic studies in, 689
  - imaging in, 687-688
  - serologic studies in, 688
  - tissue biopsies in, 687
  - urinalysis in, 688-689
- gastrointestinal features of, 686
- hematologic features of, 686
- hepatic features of, 686-687
- mast cell characteristics in, 679-681
  - mast cell mediators, 680
  - mast cell stimulators, 680-681
- pathogenesis of, 682-683
- prognosis for, 689-690
- psychologic features of, 687
- skeletal lesions in, 685-686
- spleen and lymph node involvement by, 686
- subgroups of, 681-682
- symptoms of, 683-684
- treatment of, 690-691

Medical dermatology. *See also Systemic dermatologic therapy.*

- autoimmune blistering diseases in. *See Autoimmune blistering diseases.*
- cutaneous T-cell lymphoma in. *See Cutaneous T-cell lymphoma.*
- cutaneous vasculitis in. *See Cutaneous vasculitis.*
- definition of, 587
- demise of, reasons for, 586, 587-589
- drug reactions in. *See Drug reactions.*
- hair disorders in. *See Hair disorders.*
- HIV infections in. *See HIV infections.*
- infectious diseases in. *See Infectious diseases.*

## inpatient, 593-602

- current status of, 594-595
  - diagnosis-related groups in, 593-594
  - hospitalists in, 597, 600-601
  - national perspective on, 595-596
  - non-dermatologists in, 596
  - regional centers in, 600-601
  - resident training in, 601
  - University of Miami experience with, 597-600
    - admission criteria in, 598
    - care protocols in, 598-599
    - case mix in, 599-600
    - dermatologic collaboration in, 598
    - research in, 600
    - service structure in, 597-598
  - leg ulcers in. *See Leg ulcers.*
  - mastocytosis in. *See Mastocytosis.*
  - melanoma in. *See Melanoma.*
  - preservation of, 583-592
    - challenges in, 587-589
    - family history, 585-586
    - goals for, 589-592
      - accomplishment of, 591-592
      - combined training programs, 590
      - educational debt forgiveness, 590
      - equitable grant reviews, 590
      - increased support for new careers, 590
      - increased support for orphan diseases, 591
      - increased support for research, 590
      - nongovernmental support, 591
      - history of present illness, 583-585
      - past medical history, 585
  - psoriasis in. *See Psoriasis.*
  - residency training program for, 589
  - tumor necrosis factor- $\alpha$  in. *See Tumor necrosis factor- $\alpha$ .*
- Melacine, for melanoma, 730
- Melanin, dermoscopy of, in pigmented lesions, 221-222
- Melanocytic nevi, benign. *See Benign melanocytic nevi.*
- Melanoma, 727-735
- amelanotic, diagnostic clues in, 565
  - Breslow thickness in, 727, 728
  - chemotherapy for, 729
  - classification of, 727
  - dermoscopy of, 299-305
    - blue-white veil in, 300-301
    - broadened network in, 304
    - dots and globules in, 302-303
    - false-negative melanomas, 304
    - in situ lesions, 304
    - multiple blue-gray dots in, 303
    - multiple brown dots in, 301
    - multiple colors in, 303
    - pigmentation pattern symmetry in, 300
    - pseudopods in, 302
    - radial streaming in, 301
    - scar-like depigmentation in, 302
    - single color in, 300
  - tumor thickness and, 285-297
    - case reports of, 289-296
      - in situ lesions, 289, 291
      - intermediate thickness lesions, 293
      - thick invasive lesions, 293, 295-296
      - thin invasive lesions, 291, 293
    - observational studies of, 387-289
    - progression from in situ melanoma, 286-287
  - early, dermoscopy of, 320-325
    - diagnosis of, 319-325
      - difficulties in, 319
      - growth patterns in, 319-321
    - versus atypical moles, dermoscopy of, 337-345

- methods in, 338  
 patient selection for, 338  
 results of, 338-341  
 scoring systems in, 344  
 immunotherapy for, 729-732  
   dendritic cell vaccines, 732  
   ganglioside vaccines, 730  
   gene therapy, 732  
   peptide vaccines, 731  
   shed antigen vaccines, 731-732  
   viral melanoma oncolysates, 730-731  
   whole cell vaccines, 730  
 in vivo confocal microscopy of, 374  
 interferons for, 141, 729  
 interleukins for, 729  
 mimickers of, 333  
 radiation therapy for, 732-733  
 risk stratification in, 327-335  
   algorithm for, 330-333  
   dermoscopy in, 327-328  
   pigment network in, 328-330  
   management decisions in, 333  
   management versus diagnosis in, 327  
   sentinel lymph node biopsy in, 728  
   serologic markers for, 728-729  
   surgery for, 728  
   treatment of, 729-733  
 Menkes' syndrome, and hair shaft defects, 721  
 Meropenem. See *Antibiotics, carbapenems*.  
 Metabolic effects, of glucocorticosteroids, 71-72  
 Meta-Crill, in soft-tissue augmentation, 505  
 Methemoglobinemia, dapsone and, 83, 85  
 Methotrexate. See *Cytotoxic agents*.  
 1,4-Methylimidazole acetic acid, in mastocytosis, 688-689  
 Microscopy, in vivo confocal. See *In vivo confocal microscopy*.  
 Miescher's nevi, dermoscopy of, 275  
 Milia, chemical peels and, 433-434  
   in wound repair, 794-795  
 Milia-like cysts, in dermoscopy, of pigmented lesions, 252  
   histopathologic correlates of, 265  
 Minocycline. See *Antibiotics, tetracyclines*.  
 Monobactams. See *Antibiotics*.  
 Mucous membrane pemphigoid, treatment of, 639-641  
 Musculoskeletal effects, of antimalarial agents, 154-155  
   of glucocorticosteroids, 67-70  
 Mycophenolate mofetil. See *Cytotoxic agents*.  
 Mycosis fungoides, and hair follicle destruction, 719  
 Myelosuppression, azathioprine and, 110  
 Myopathy, antimalarial agents and, 154-155  
   glucocorticosteroids and, 70  
  
 Nail infections, griseofulvin for, 36  
 Naltrexone. See *Psychiatric agents*.  
 Nasal rima, elevated, diagnostic clues in, 565  
 Nasolabial fold, fat grafting in, 530  
 Nd:YAG laser therapy, for leg veins, 472  
 Neck rejuvenation, 387-396  
   anatomy in, 387-388  
   complications of, 395-396  
   physiology of aging in, 388-389  
   techniques for, 389-395  
   botulinum toxin, 395  
   chemical peel, 390  
   laser resurfacing, 390-391  
   liposculpture, 392, 395  
   platysmaplasty, 391-392  
   S-plasty, 392  
 Necrotizing fasciitis, treatment of, 752  
 Negative pigmented network, in dermoscopy, of pigmented lesions, 250  
 Nelfinavir, for HIV infections, 28, 766-767  
 Nephrotoxicity, of cyclosporine, 127  
 Nervous system effects, of glucocorticosteroids, 71  
 Neuralgia, postherpetic, amitriptyline for, 182  
   gabapentin for, 190  
   thalidomide for, 97  
 Neuroleptic malignant syndrome, pimozide and, 192  
 Neurologic effects, of dapsone, 84  
 Neuropathic pain syndrome, amitriptyline for, 181-182  
 Neuropathy, diabetic, gabapentin for, 190  
 Neurotropic agents. See *Psychiatric agents*.  
 Neutrophilic disorders, dapsone for, 82  
   drug-induced, 698  
   sulfapyridine for, 82  
 Nevi, benign melanocytic. See *Benign melanocytic nevi*.  
   dysplastic, versus early melanoma. See *Melanoma*.  
 Nevirapine, for HIV infections, 27-28, 762-763  
 Newcastle disease virus, for melanoma, 731  
 New-Fill, in soft-tissue augmentation, 505  
 Nicorandil, and oral ulcers, 697-698  
 Nonmelanoma skin cancer, in vivo confocal microscopy of, 371, 373  
 Nonnucleoside reverse transcriptase inhibitors, for HIV infections, 27-28, 762-764  
 Nonsteroidal anti-inflammatory drugs, adverse reactions to, 704  
 Norfloxacin. See *Antibiotics, fluoroquinolones*.  
 Nortriptyline, dermatologic uses of, 182  
 Nuclear transcription factors, in psoriasis, 650  
 Nucleoside reverse transcriptase inhibitors, for HIV infections, 26-27, 758-762, 769  
 Nucleotide reverse transcriptase inhibitors, for HIV infections, 28, 769  
  
 Oasis, indications for, 557-558  
 Obsessive-compulsive disorder, selective serotonin reuptake inhibitors for, 185  
 Obstetric effects, of glucocorticosteroids, 73  
 Ocular effects, of mucous membrane pemphigoid, 640  
 Ofloxacin. See *Antibiotics, fluoroquinolones*.  
 Onychomycosis, itraconazole for, 40  
   terbinafine for, 45  
 Open comedo-like structures, in dermoscopy, of pigmented lesions, 252  
   histopathologic correlates of, 265  
 Ophthalmologic effects, of antimalarial agents, 156-157  
   of glucocorticosteroids, 70-71  
 Oral contraceptives, dermatologic uses of, 171  
 Oral ulcers, cyclophosphamide for, 115  
   nicorandil and, 697-698  
 Orbital hemorrhage, brow lift and blepharoplasty and, 533  
 Osmotic agents, in sclerotherapy, 476  
 Osteonecrosis, glucocorticosteroids and, 69-70  
 Osteopathy, methotrexate and, 114  
 Osteopenia, antiretroviral therapy and, 768  
 Osteoporosis, antiretroviral therapy and, 768  
   glucocorticosteroids and, 67-69  
 Ovarian androgen suppression, for acne, 174  
   for hirsutism, 175  
  
 Paraneoplastic pemphigus, prognosis for, 645

- Parasitosis, delusions of, pimozone for, 191
- Parkinson-like effects, of pimozone, 192
- Paroxetine. See *Psychiatric agents, selective serotonin reuptake inhibitors.*
- Pemphigoid, bullous, treatment of, 637-639
- cyclophosphamide for, 115
  - dapsone for, 82
  - mucous membrane, treatment of, 639-641
  - mycophenolate mofetil for, 106
- Pemphigus, cyclophosphamide for, 115
- mycophenolate mofetil for, 106-107
  - paraneoplastic, prognosis for, 645
  - treatment of, 643-645
- Penicillium marneffei* infections, treatment of, 753
- Pentafuside, for HIV infections, 769
- Peptic ulcer disease, glucocorticosteroids and, 73-74
- Peptide vaccines, for melanoma, 731
- Peripheral neuropathy, thalidomide and, 98
- Persistent nevi, clinical features of, 333
- Photoaging skin, chemical peels for. See *Chemical peels.*
- consultation for, 401-403
  - Fitzpatrick classification in, 402
  - Glogau classification in, 402-403
- Photoderm VI laser therapy, for leg veins, 472-473
- Photodermatoses, cyclosporine for, 124
- Photographic documentation, tips for, 577
- Photopheresis, extracorporeal, for epidermolysis bullosa acquisita, 642
- Photosensitivity, to fluoroquinolones, 10
- Pigment network, in dermoscopy, of pigmented lesions, 229, 234
- histopathologic correlates of, 260-261
  - in risk stratification, for melanoma, 328-330
- Pigment pattern, in dermoscopy, of melanoma, 300
- of pigmented lesions, 222, 229
- Pigmentary dyschromias, chemical peels for, 420-421
- Pigmentation, changes in, antimalarial agents and, 155
- chemical peels and, 406-407, 410, 428-429
  - dermabrasion and, 441-442
  - erbium:YAG laser resurfacing and, 462
  - in wound repair, 794
  - in dermoscopy, of pigmented lesions, histopathologic correlates of, 263-264
- Pigmented lesions, clinical features of, 333
- dermoscopy of, blue-white veil in, 222
  - borders in, 255
  - branched streaks in, 249-250
  - dots and globules in, 240
  - erythema in, 222
  - fissures in, 252
  - follicular plugs in, 255
  - granules in, 240
  - histopathologic correlates of, 259-268
    - blue-white veil, 263
    - central white patch, 267
    - dots and globules, 261
    - exophytic papillary structures, 265-266
    - hypopigmentation, 264
    - lacunae, 266-267
    - leaf-like structures, 267
    - milium-like cysts, 265
    - open comedo-like structures, 265
    - pigment network, 260-261
    - radial streaming and pseudopods, 261, 263
    - regression structures, 265
    - sources of pigmentation, 263-264
    - vasculature, 265  - historical aspects of, 221
  - lacunae in, 222
  - leaf-like structures in, 255
  - melanin in, 221-222
  - milium-like cysts in, 252
  - negative pigmented network in, 250
  - open comedo-like structures in, 252
  - pigment network in, 229, 234
  - pigment pattern in, 222, 229
  - pigmented pseudonetwork in, 252
  - radial streaming and pseudopods in, 248-249
  - regression structures in, 240, 248
  - sources of pigmentation in, 221-222, 229
  - structureless areas in, 234-235, 240
  - telangiectasia in, 222
  - vasculature in, 222
  - in vivo confocal microscopy of, 373-374
- Pigmented pseudonetwork, in dermoscopy, of pigmented lesions, 252
- Pimozone. See *Psychiatric agents.*
- Plain films, of mastocytosis, 687-688
- Plasmagel, in soft-tissue augmentation, 502
- Platysmaplasty, for aging neck, 391-392
- PMS-350, in soft-tissue augmentation, 503
- Pneumocystis carinii* infections, glucocorticosteroids and, 73
- Pneumonitis, methotrexate and, 114
- Polidocanol, in sclerotherapy, 481
- Polyarteritis nodosa, cyclophosphamide for, 115
- diagnosis of, 606
- Polymethylmethacrylate, in soft-tissue augmentation, 503-504
- Polymorphous light eruption, antimalarial agents for, 153
- azathioprine for, 109
- Porcine xenografts, in wound repair, 789-790
- Porphyria cutanea tarda, antimalarial agents for, 152-153
- Postherpetic neuralgia, amitriptyline for, 182
- gabapentin for, 190
  - thalidomide for, 97
- Prednisone, for bullous pemphigoid, 638
- for mucous membrane pemphigoid, 640
  - for pemphigus, 644-645
- Pregnancy, and telogen effluvium, 713
- antimalarial agents in, 154
  - glucocorticosteroids in, 73
  - selective serotonin reuptake inhibitors in, 186
- Profill, in soft-tissue augmentation, 505-506
- Protease inhibitors, for HIV infections, 28, 764-767, 769
- Proud flesh, in wound repair, 793-794
- Prurigo nodularis, thalidomide for, 95
- Pruritus, chemical peels and, 433
- thalidomide for, 97
- Pseudopods, in dermoscopy, of melanoma, 302
- of pigmented lesions, 248-249
  - histopathologic correlates of, 261, 263
- Pseudotumor cerebri, glucocorticosteroids and, 71
- Psoralen plus ultraviolet A therapy, for mastocytosis, 690
- with interferons, for cutaneous T-cell lymphoma, 739-740
- Psoriasis, 649-657
- acute pustular, versus acute generalized exanthematic pustulosis, 699
  - alefacept for, 654-655
  - anti CD-80 for, 653-654
  - anti CD11a Hu1124 for, 653
  - anti-interleukin-8 for, 652
  - antimalarial agents for, 153-154
  - CTLA4lg for, 655
  - cyclosporine for, 123-124
  - daclizumab for, 654

- etanercept for, 652  
etretinate-acitretin for, 164-165  
immune deviation for, 653  
immunopathogenesis of, 649-651  
  antigen-presenting cells in, 650  
  cytokine classification in, 650  
  nuclear transcription factors in, 650  
  T cell activation in, 650  
  T cells in, 649  
  T lymphocyte trafficking in, 650-651  
infliximab for, 651-652  
methotrexate for, 112  
mycophenolate mofetil for, 106  
tacrolimus for, 130  
thioguanine for, 110-111  
treatment of, challenges in, 651  
  future trends in, 655  
Psoriatic arthritis, etanercept for, 622  
Psychiatric agents, 179-197  
  gabapentin, 189-190  
    adverse effects of, 190  
    dermatologic uses of, 190  
    mechanism of action of, 189-190  
    pharmacology of, 189  
    therapeutic guidelines for, 190  
  naltrexone, 187-189  
    adverse effects of, 189  
    drug interactions with, 189  
    mechanism of action of, 187-189  
    pharmacology of, 187  
    therapeutic guidelines for, 189  
  pimozide, 190-193  
    adverse effects of, 191-192  
    dermatologic uses of, 191  
    drug interactions with, 193  
    mechanism of action of, 191  
    monitoring guidelines for, 192-193  
    pharmacology of, 191  
  selective serotonin reuptake inhibitors, 184-187  
    adverse effects of, 185-186  
    dermatologic uses of, 184-185  
    drug interactions with, 187  
    monitoring guidelines for, 186  
    pharmacology of, 184  
    therapeutic guidelines for, 186-187  
  tricyclic antidepressants, 179-184  
    adverse effects of, 183  
    dermatologic uses of, 181-182  
    drug interactions with, 183  
    mechanism of action of, 179-181  
    monitoring guidelines for, 184  
    pharmacology of, 179  
Psychogenic excoriations, selective serotonin reuptake inhibitors for, 185  
Psychotropic agents. *See Psychiatric agents.*  
Pulse steroids, for pemphigus, 645  
Pulsed dye laser therapy, for aging neck, 391  
  in vivo confocal microscopy after, 375  
Pustulosis, acute generalized exanthematic, drug-induced, 698-700  
Pyoderma gangrenosum, cyclophosphamide for, 114-115  
  cyclosporine for, 124  
  leg ulcers in, 671-673  
  tacrolimus for, 130  
  thalidomide for, 96-97  
Pyodermas, rifamycins for, 12  
Radial streaming, in dermoscopy, of melanoma, 301  
  of pigmented lesions, 248-249  
  histopathologic correlates of, 261, 263  
Radiation therapy, for mastocytosis, 691  
  for melanoma, 732-733  
Raynaud's disease, leg ulcers in, 661-662  
Rebetron, for chronic viral hepatitis, 29-30  
Recombinant human collagen, in soft-tissue augmentation, 505  
Recombinant platelet-derived growth factor, for leg ulcers, 675-676  
  in wound repair, 790  
5 $\alpha$ -Reductase, dermatologic uses of, 170-171  
  inhibition of, for acne, 174  
  for hirsutism, 176  
Regression structures, in dermoscopy, of pigmented lesions, 240, 248  
  histopathologic correlates of, 265  
Resoplast, in soft-tissue augmentation, 504  
Restylane, in soft-tissue augmentation, 501  
Restylane-Fine, in soft-tissue augmentation, 501-502  
Retinoids, 161-167  
  adverse effects of, 162-163  
  for acne, 163-164  
    complications of, 164  
  for cutaneous T-cell lymphoma. *See Cutaneous T-cell lymphoma.*  
  for disorders of cornification, 165  
  for psoriasis, 164-165  
  historical aspects of, 161  
  mechanism of action of, 161-162  
  to prevent skin cancer, 165-166  
  with interferons, for skin cancer, 166  
Retinopathy, antimalarial agents and, 156-157  
Reviderm-Intra, in soft-tissue augmentation, 506  
Rheumatoid arthritis, etanercept for, 622  
  infliximab for, with methotrexate, 625  
  tumor necrosis factor- $\alpha$  in, 620  
Ribavirin, with interferons, for chronic viral hepatitis, 29-30  
Rifabutin. *See Antibiotics, rifamycins.*  
Rifampin. *See Antibiotics, rifamycins.*  
Rifamycins. *See Antibiotics.*  
Ritonavir, for HIV infections, 28, 766, 767  
S100 protein, as marker, for melanoma, 728-729  
Saqinavir, for HIV infections, 28, 765-766  
Sarcoidosis, and hair follicle destruction, 718  
  antimalarial agents for, 153  
  methotrexate for, 113  
  thalidomide for, 95  
Scalp lesions, diagnostic clues in, 564  
Scar-like depigmentation, in dermoscopy, of melanoma, 302  
Scarring, chemical peels and, 429-432  
  chemical peels for, 407  
  dermabrasion and, 442  
  erbium:YAG laser resurfacing and, 463  
Scleroderma, and hair follicle destruction, 718  
Sclerolase laser therapy, for leg veins, 472  
Sclerotherapy, 475-481  
  agents used in, 476-477  
  dosage of, 477  
  chemical irritants in, 476  
  complications of, 480-481  
  compression stockings after, 479-480  
  contraindications to, 476  
  detergent agents in, 476  
Quinacrine. *See Antimalarial agents.*

Sclerotherapy (*Continued*)

- hypertonic saline in, 481
- osmotic agents in, 476
- patient selection for, 475-476
- polidocanol in, 481
- sodium tetradecyl sulfate in, 481
- technique for, 477-480
  - injection techniques, 479
  - skin tension, 479
- SCORTEN index, of drug reactions, 704-705
- Seborrheic keratoses, clinical features of, 333
- dermoscopy of, 347-348
- Sedation, tips for, 577
- Selective serotonin reuptake inhibitors. *See Psychiatric agents.*
- Sentinel lymph nodes, biopsy of, in melanoma, 728
- Serologic markers, for melanoma, 728-729
- Serologic studies, of mastocytosis, 688
- Seromas, in wound repair, 793
- Sertraline. *See Psychiatric agents, selective serotonin reuptake inhibitors.*
- Shed antigen vaccines, for melanoma, 731-732
- Shock, azathioprine and, 110
- Silicones, in soft-tissue augmentation, 502-503
- Silikon-1000, in soft-tissue augmentation, 502-503
- Sjögren's syndrome, antimalarial agents for, 153
- Skeletal effects, of retinoids, 162-163
- Skeletal lesions, in mastocytosis, 685-686
- Skin cancer, facial flaps for. *See Facial flaps.*
- nonmelanoma, in vivo confocal microscopy of, 371, 373
  - prevention of, retinoids in, 165-166
  - retinoids for, with interferons, 166
- Skin expansion, in wound repair, 545, 548
- Skin filling. *See Soft-tissue augmentation.*
- Skin grafts, in wound repair, 548, 550-552
- Skin substitutes, 555-561
  - AlloDerm, 558
  - Biobrane, 557
  - cadaveric, 558
  - composite grafts, 559-560
  - epidermal grafts, 555-557
  - E-Z-Derm, 557
  - Integra, 558
  - Oasis, 557-558
  - TransCyte, 559
- Skin texture, changes in, chemical peels and, 433
- Small vessel disease, sclerotherapy for. *See Sclerotherapy.*
- Smoking, and antimalarial therapy, 152
- Sodium tetradecyl sulfate, in sclerotherapy, 481
- Soft-tissue augmentation, 491-508
  - agents used in, 492, 505-506
  - allogeneic products in, 503-504
  - autologous products in, 502-503
  - Botox in, 500
  - bovine collagen products in, 504
  - choice of implant for, 492
  - fat in, 497-500
    - complications of, 499
    - donor site in, 498
    - freezing of, for later use, 499
    - harvest of, 498
    - historical aspects of, 497-498
    - technique for, 498-499
  - future trends in, 506
  - human placental collagen in, 504
  - hyaluronic acid products in, 500-502
  - recombinant collagen in, 505
  - Zyderm/Zyplast in, 493-497
    - complications of, 497
    - composition of, 493-494
    - for lip enhancement, 496-497
    - historical aspects of, 493
    - hypersensitivity reactions to, 497
    - in combination with other products, 495
    - indications for, 496
    - patient selection for, 494
    - results of, 495-496
    - skin testing in, 494
    - technique for, 494-497
- Solar lentigines, dermoscopy of, 348-351
- Solar urticaria, antimalarial agents for, 153
- Spironolactone, dermatologic uses of, 172
- Spitz nevi, dermoscopy of, 280-282
- S-plasty, for aging neck, 392
- Spleen, involvement of, by mastocytosis, 686
- Spondyloarthropathies, infliximab for, 625
- Squamous cell carcinoma, interferons for, 142
- Staphylococcal diseases. *See Infectious diseases.*
- Stavudine, for HIV infections, 26-27, 761
- Steroid withdrawal syndrome, glucocorticosteroids and, 74
- Steroids, for bullous pemphigoid, 638
  - for drug reactions, 703-704
  - for erythema, after chemical peels, 431
  - for hypersensitivity syndrome, 707
  - for linear IgA bullous dermatosis, 643
  - for mastocytosis, 690
  - for mucous membrane pemphigoid, 640
  - for pemphigus, 644-645
  - for pyoderma gangrenosum, 672
  - for toxic epidermal necrolysis, 706
- Stevens-Johnson syndrome, drug-induced, 700-703
  - treatment of, 705-706
- Streptococcal diseases. *See Infectious diseases.*
- Streptogramins. *See Antibiotics.*
- Structureless areas, in dermoscopy, of pigmented lesions, 234-235, 240
- Subacute cutaneous lupus erythematosus, thalidomide for, 93-94
- Subcutaneous fat atrophy, glucocorticosteroids and, 74
- Subungual pigmentation, surgical tips for, 563
- Sulfapyridine, 79-86
  - absorption and distribution of, 80
  - dermatologic uses of, 82
  - drug interactions with, 84
  - historical aspects of, 79
  - metabolism and excretion of, 80
  - monitoring guidelines for, 84-85
  - structure of, 79
- Sure Closure stretching device, in wound repair, 548
- Surface microscopy. *See Dermoscopy.*
- Surgical tips, 563-577, 773-786
  - diagnostic clues, 564-565
    - amelanotic melanoma, 565
    - cancerous versus benign lesions, 564-565
    - dispersed pattern basal cell carcinomas, 565
    - elevated nasal rims, 565
    - listen to patient, 565
    - scalp, 564
  - for anesthesia, 775-777
  - for biopsies, 565, 568, 784
  - for conscious sedation, 577
  - for digit surgery, 563-564
  - hair control, 563-564
    - subungual pigmentation, 563
  - toeweb nevus, 563
  - for photographic documentation, 577
  - for wound management, 568-573, 784-785
  - eyeglass management, 572-573



- healing by secondary intention, 568  
 immobile dressings, 572  
 partial closure/guiding suture, 570  
 pressure dressings, 571, 784-785  
 protective ear dressings, 572  
 purse-string partial closure, 568, 570  
 tape-sensitive skin, 572  
 intraoperative, 573-577, 777-783  
   chalazion clamps, 777  
   corneal shields, 777-778  
   cotton swabs, 779, 781  
   dissecting scissors, 778-779  
   hair management, 781, 783  
   hemostasis, 573, 575  
   more local anesthetic, 575  
   preventing ectropion, 576-577  
   scalpel handles, 779  
   septal elevators, 779  
   serrated tissue scissors, 777  
   short sutures, 575  
   skin hooks, 777  
   suture placement and removal, 783-784  
   thermoplastic material, 781  
   tissue marking, 575  
 preappointment, 773  
 preoperative, 773-775  
 Suture Tension Adjustment Reel, in wound repair, 545, 548  
 Sutures, in wound repair. *See* *Wound repair*.  
   tips for. *See* *Surgical tips*.  
 Sweet's syndrome, drug-induced, 698  
 Syndrome of inappropriate secretion of antidiuretic hormone, selective serotonin reuptake inhibitors and, 186  
 Systemic dermatologic therapy. *See also* *Medical dermatology*.  
   antibiotics in. *See* *Antibiotics*.  
   antifungal agents in. *See* *Antifungal agents*.  
   antihistamines in. *See* *Antihistamines*.  
   antimalarial agents in. *See* *Antimalarial agents*.  
   antiviral agents in. *See* *Antiviral agents*.  
   cyclosporine in. *See* *Cyclosporine*.  
   cytotoxic agents in. *See* *Cytotoxic agents*.  
   dapson in. *See* *Dapsone*.  
   glucocorticosteroids in. *See* *Glucocorticosteroids*.  
   hormonal therapy in. *See* *Hormonal therapy*.  
   interferons in. *See* *Interferons*.  
   psychiatric agents in. *See* *Psychiatric agents*.  
   retinoids in. *See* *Retinoids*.  
   sulfapyridine in. *See* *Sulfapyridine*.  
   tacrolimus in. *See* *Tacrolimus*.  
   thalidomide in. *See* *Thalidomide*.  
 Systemic lupus erythematosus, and anagen arrest, 716  
   and hair follicle destruction, 718  
   methotrexate for, 112  
   thalidomide for, 94  
  
 T-20, for HIV infections, 769  
 T cells, in psoriasis, 649, 650  
 T lymphocytes, in psoriasis, 650-651  
 Tacrolimus, 129-132  
   adverse effects of, 132  
   caution in, 132  
   dermatologic uses of, 129-131  
     alopecia, 130  
     atopic dermatitis, 129-130  
     Behçet's disease, 130-131  
     graft-versus-host disease, 131  
     lichen planus, 131  
     psoriasis, 130  
     pyoderma gangrenosum, 130, 672  
   dosage of, 131  
   drug interactions with, 131  
   monitoring guidelines for, 132  
   pharmacology of, 129  
 Tardive dyskinesia, pimozide and, 192  
 T-cell lymphoma, cutaneous. *See* *Cutaneous T-cell lymphoma*.  
 Telangiectasia, in dermoscopy, of pigmented lesions, 222  
 Telangiectasia macularis eruptiva perstans, in mastocytosis, 684, 685  
 Telemedicine, 379-385  
   collaborative technologies and, 382-385  
     e-mail, 382  
     Lotus Notes and variants, 382-383  
     video and whiteboard, 383-385  
   historical aspects of, 379-380  
   Internet and, 380-381  
   prehistory of, 381-382  
 Telogen effluvium. *See* *Hair disorders*.  
 Telogen phase, of hair growth, 711-712  
 Tenofovir disoproxil fumarate, for HIV infections, 769  
 Teratogenicity, of retinoids, 162  
   of thalidomide, 97-98  
 Terbinafine. *See* *Antifungal agents*.  
 Tetracyclines. *See* *Antibiotics*.  
 Thalidomide, 87-103  
   adverse effects of, 97-98  
   cost of, 99  
   dermatologic uses of, 89-97  
     actinic prurigo, 94-95  
     aphthous stomatitis, 90  
     Behçet's disease, 91-92  
     chronic graft-versus-host disease, 92-93  
     cutaneous sarcoidosis, 95  
     erythema multiforme, 96  
     erythema nodosum leprosum, 89-90  
     HIV-associated aphthous ulceration, 90-91  
     Jessen's lymphocytic skin infiltration, 96  
     Kaposi's sarcoma, 97  
     Langerhans' cell histiocytosis, 95-96  
     lichen planus, 97  
     lupus erythematosus, 93-94  
     postherpetic neuralgia, 97  
     prurigo nodularis, 95  
     pruritus, 97  
     pyoderma gangrenosum, 96-97  
     to modulate tumor necrosis factor- $\alpha$ . *See* *Tumor necrosis factor- $\alpha$* .  
     toxic epidermal necrolysis, 96, 706  
   drug interactions with, 98  
   mechanism of action of, 88-89  
   pharmacokinetics of, 87-88  
   pharmacology of, 87  
   regulatory guidelines for, 98-99  
   therapeutic and monitoring guidelines for, 99-100  
 Thioguanine. *See* *Cytotoxic agents*.  
 Thiopurine methyltransferase level, in azathioprine therapy, 638  
 Thromboangiitis obliterans, leg ulcers in, 663  
 Thyroid disorders, and telogen effluvium, 713  
 Tinea capitis, fluconazole for, 43  
   griseofulvin for, 36  
   itraconazole for, 40-41  
   ketoconazole for, 38  
   terbinafine for, 45  
 Tinea pedis, terbinafine for, 44  
 Toeweb nevus, surgical tips for, 563

- Toxic epidermal necrolysis, cyclophosphamide for, 115  
 cyclosporine for, 125-126  
 drug-induced, 700-703  
   treatment of, 705-706  
 thalidomide for, 96, 627-628
- Toxic shock syndrome, in neonates, 752
- Streptococcal, treatment of, 750-751  
 treatment of, 750
- Toxin-mediated infectious diseases. *See Infectious diseases.*
- TransCyte, indications for, 559
- Transplant recipients, skin cancer in, prevention of, retinoids in, 166
- Trichloroacetic acid, in chemical peels. *See Chemical peels.*
- Trichothiodystrophy, and hair shaft defects, 721
- Trichotillomania, clomipramine for, 182  
 selective serotonin reuptake inhibitors for, 185
- Tricyclic antidepressants. *See Psychiatric agents.*
- Trimethoprim-sulfamethoxazole. *See Antibiotics.*
- Trofloxacin. *See Antibiotics, fluoroquinolones.*
- Tryptase, in mastocytosis, 688
- Tuberculosis, reactivation of, glucocorticosteroids and, 73
- Tumor necrosis factor- $\alpha$ , biology of, 617-619  
 modulation of, 617-635  
   etanercept in, 620-623  
     dosing and administration of, 622  
     efficacy of, 622  
     indications for, 621-622  
     mechanism of action of, 621  
     pharmacology of, 621  
     safety and toxicity of, 623  
     structure of, 620-621  
   indications for, 619-620  
   infliximab in, 623-626  
     dosing and administration of, 625-626  
     efficacy of, 625  
     indications for, 625  
     mechanism of action of, 623, 625  
     pharmacology of, 625  
     safety and toxicity of, 626  
     structure of, 623  
   thalidomide in, 626-629  
     dosing and administration of, 628-629  
     efficacy of, 627-628  
     indications for, 627-628  
     mechanism of action of, 626  
     pharmacology of, 626-627  
     safety and toxicity of, 629  
     structure of, 626
- Ulcers, of leg. *See Leg ulcers.*  
 oral, cyclophosphamide for, 115  
 nicorandil and, 697-698
- Ultraviolet radiation, in apoptosis, tumor necrosis factor- $\alpha$  with, 619
- Unna's nevi, dermoscopy of, 275
- Uremic pruritus, thalidomide for, 97
- Urinalysis, in mastocytosis, 688-689
- Urticaria, cold, chemical peels and, 434  
 doxepin for, 181  
 solar, antimalarial agents for, 153
- Urticaria pigmentosa, in mastocytosis, 684, 685
- Urticarial vasculitis, diagnosis of, 606, 609  
 treatment of, 613
- Vaccines, for melanoma. *See Melanoma.*
- Vaccinia melanoma oncolysate, for melanoma, 731
- Valacyclovir, for herpes simplex virus infections, 25  
 for varicella-zoster virus infections, 25
- Varicella-zoster virus infections, antiviral agents for. *See Antiviral agents.*
- Varicose veins, factors predisposing to, 476  
 leg ulcers in, 670  
 sclerotherapy for. *See Sclerotherapy.*
- Vascular lesions, clinical features of, 333
- Vascular tumors, interferons for, 142
- Vasculature, in dermoscopy, of pigmented lesions, 222  
 histopathologic correlates of, 265
- Vasculitis laser therapy, for leg veins, 472
- Vasculitis, cutaneous. *See Cutaneous vasculitis.*  
 dapsone for, 82  
 hypocomplementemic urticarial, cyclophosphamide for, 115
- Veno-occlusive disease, hepatic, thioguanine and, 111
- Venous stasis dermatitis, leg ulcers in, 670
- Vibrio infections, treatment of, 753-754
- Video network systems, and telemedicine, 383-385
- Viral infections, and drug reactions, 702
- Viral melanoma oncolysates, for melanoma, 730-731
- Wegener's granulomatosis, diagnosis of, 610
- Weight gain, glucocorticosteroids and, 72
- Whole cell vaccines, for melanoma, 730
- Wound repair, 535-553, 787-797  
 after chemical peels, 430-431  
 age in, 535  
 analgesia in, 790  
 by secondary intention, 538-539  
 circulatory embarrassment in, 536  
 complications of, 790-795  
   bleeding, 791  
   chondritis, 795  
   contact dermatitis, 793  
   dehiscence, 792-793  
   excessive granulation tissue, 793-794  
   infections, 791-792  
   pigmentary changes, 794  
   seroma, 793  
   suture problems, 794-795  
   tissue necrosis, 794  
 diet in, 535  
 dressings in, 787-790  
   biologic, 789  
   tissue adhesives, 789  
 early remodeling in, 795  
 free margins in, 536  
 full-thickness skin grafts in, 548, 550-552  
 health status in, 535  
 impaired, glucocorticosteroids and, 74  
 intraoperative skin expansion in, 545, 548  
 luminal patency in, 536  
 medications in, 535-536  
 neural injury in, 536  
 patient lifestyle in, 537  
 porcine xenografts in, 789-790  
 pressure locations in, 536-537  
 primary closure in, 541-545  
   buried purse-string sutures in, 545  
   buried sutures in, 541, 543  
   presuturing in, 541  
   pulley sutures in, 543, 545  
   staged excision in, 541  
   undermining in, 541

- recombinant platelet-derived growth factor in, 790  
secondary closure in, 539, 541  
tips for. See *Surgical tips*.  
tumor necrosis factor- $\alpha$  in, 620  
vascular supply in, 536  
wound care in, 536
- Xenografts, porcine, in wound repair, 789-790  
Xeroderma pigmentosum, skin cancer in, prevention of,  
retinoids in, 165-166
- Yeast infections, erbium:YAG laser resurfacing and,  
462-463
- Zalcitabine, for HIV infections, 26-27, 761  
Zidovudine, for HIV infections, 26-27, 758-759, 761, 762  
Zithromax. See *Antibiotics, macrolides*.  
Zyderm, in soft-tissue augmentation. See *Soft-tissue  
augmentation*.  
Zyplast, in soft-tissue augmentation. See *Soft-tissue  
augmentation*.